California-based medical equipment manufacturer Resmed Inc. (RMD) launched a continuous and automatic positive-airway pressure (:PAP) device platform titled “AirSense 10.” The AirSense 10 ...

CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, breathing health, and ...

ResMed stock (NYSE: RMD), a respiratory care devices company, currently trades at $150 per share, 23% below the level seen in March 2021, and it has room for growth, in our view. RMD stock was ...

ResMed CEO on how wearables, GLP-1s will impact sleep apnea device sales. CEO Mick Farrell sees the ‘two tidal waves’ of innovation driving more people to ResMed’s devices.

Oct 24 (Reuters) - ResMed (RMD.N), opens new tab beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for its devices used for sleep apnea treatment. Shares of the ...